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Neurobiology of Disease
The Expression of MicroRNAmiR-107 Decreases Early in
Alzheimer’s Disease andMay Accelerate Disease Progression
through Regulation of -Site Amyloid Precursor Protein-
Cleaving Enzyme 1
Wang-XiaWang,1* BernardW. Rajeev,1* Arnold J. Stromberg,2Na Ren,2 Guiliang Tang,3 Qingwei Huang,1
Isidore Rigoutsos,5 and Peter T. Nelson1,4
1Sanders-Brown Center on Aging, 2Department of Statistics, 3Department of Plant Sciences, and 4Department of Pathology and Division of Neuropathology,
University of Kentucky, Lexington, Kentucky 40536, and 5Bioinformatics and Pattern Discovery Group, IBM Thomas J. Watson Research Center, Yorktown
Heights, New York 10598
MicroRNAs (miRNAs) are small regulatory RNAs that participate in posttranscriptional gene regulation in a sequence-specific manner.
However, little is understood about the role(s) ofmiRNAs in Alzheimer’s disease (AD).We usedmiRNA expressionmicroarrays on RNA
extracted from human brain tissue from the University of Kentucky Alzheimer’s Disease Center Brain Bank with near-optimal clinico-
pathological correlation. Cases were separated into four groups: elderly nondemented with negligible AD-type pathology, nondemented
with incipient AD pathology, mild cognitive impairment (MCI) with moderate AD pathology, and AD. Among the AD-related miRNA
expression changes, miR-107 was exceptional because miR-107 levels decreased significantly even in patients with the earliest stages of
pathology. In situ hybridization with cross-comparison to neuropathology demonstrated that particular cerebral cortical laminas in-
volved by AD pathology exhibit diminished neuronal miR-107 expression. Computational analysis predicted that the 3-untranslated
region (UTR) of -site amyloid precursor protein-cleaving enzyme 1 (BACE1) mRNA is targeted multiply by miR-107. From the same
RNAmaterial analyzed onmiRNAmicroarrays,mRNAexpression profilingwas performedusingAffymetrix ExonArraymicroarrays on
nondemented, MCI, and AD patients. BACE1mRNA levels tended to increase as miR-107 levels decreased in the progression of AD. Cell
culture reporter assays performedwith a subset of the predictedmiR-107 binding sites indicate the presence of at least one physiological
miR-107 miRNA recognition sequence in the 3-UTR of BACE1 mRNA. Together, the coordinated application of miRNA profiling,
Affymetrixmicroarrays, new bioinformatics predictions, in situ hybridization, and biochemical validation indicate thatmiR-107may be
involved in accelerated disease progression through regulation of BACE1.
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Introduction
MicroRNAs (miRNAs) are small regulatory RNAs with potent
roles in metabolism, neurodevelopment, neuroplasticity, apo-
ptosis, and other fundamental neurobiological processes (for re-
view, see Nelson et al., 2003; Kosik and Krichevsky, 2005).
miRNAs exert their function through base-pairing with specific
“target”mRNAswith partially complementary sequences, result-
ing in decreased polypeptide formation from thosemRNAs (Am-
bros, 2004). Depending on the algorithm used, bioinformatics
predict that miRNAs regulate from 30% of human genes (Lewis
et al., 2003, 2005) to as much as 92% (Miranda et al., 2006).
The study of miRNA biology is in its infancy, particularly in
the human brain. Researchers have shown that RNA is patholog-
ically altered in Alzheimer’s disease (AD) brains (Ginsberg et al.,
1997; Honda et al., 2005; Ding et al., 2006; Nelson and Keller,
2007). However, a role for miRNAs in the progression of AD has
not been established firmly. Previous studies demonstrated that a
subset of miRNAs show altered expression in advanced AD, and
these changesmay be stimulated by reactivemetal elements in the
brain (Lukiw, 2007; Lukiw and Pogue, 2007). These previous
studies in AD brains were limited in the number of miRNAs that
were evaluated.
Expression profiling has provided important insights into
miRNA biology. Microarray studies have helped to describe
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which miRNAs are expressed during vari-
ous normal and abnormal brain states, in-
cluding in brain diseases (Babak et al.,
2004; Ciafre et al., 2005; Nelson et al.,
2006; Perkins et al., 2007). Although
miRNA expression analyses can provide
groundbreaking data for this novel re-
search field, miRNA profiling benefits
from the parallel use of more than a single
technique. Previous work confirmed that
understanding cellular level expression
patterns is vitally important for brain
miRNA studies (Nelson et al., 2006). In
situ hybridization (ISH) pinpoints exactly
where specific miRNAs are expressed:
neurons, astrocytes, oligodendrocytes,
microglia, and/or vasculature. Neurode-
generative diseases tend to affect distinct
cell populations. Hence, knowing which
miRNAs are expressed in which cell popu-
lations can facilitate the identification of
disease-relevant miRNA genes and their
mRNA targets.
-Site amyloid precursor protein-
cleaving enzyme 1 (BACE1) is a protein-
coding gene known to be important inAD.
BACE1 protein is an endopeptidase that
cleaves the-amyloid precursor protein to
generate neurotoxic -amyloid peptide
A1–42 (Vassar et al., 1999; Haniu et al.,
2000). The dysregulation of BACE1 may
play amajor role in the pathogenesis of AD
(Dominguez et al., 2004; Durham and
Shepherd, 2006; Guo and Hobbs, 2006;
John, 2006). BACE1 is enriched in neu-
rons (Bigl et al., 2000; Fukumoto et al., 2002) and its expression is
regulated posttranscriptionally (Marambaud et al., 1998; Rossner
et al., 2006). However, BACE1 gene expression regulation is not
completely understood. Here, we provide data indicating that
miR-107 contributes to BACE1 posttranscriptional regulation
and that this pathway is predicted to exacerbate pathology in AD
brains.
Materials andMethods
RNA isolation from a human cerebral cortex. RNA was extracted from
snap-frozen brain tissue from the University of Kentucky Alzheimer’s
Disease Brain Bank under a University of Kentucky Institutional Review
Board protocol. Premortem clinical evaluations were exhaustive, and the
last cognitive evaluation was performed usually within the last year of life
as described previously (Schmitt et al., 2000). Clinical diagnoses were
established at Consensus Conference with University of Kentucky neu-
ropsychologists, neurologists, and neuropathologists. The inclusion cri-
teria that we applied were as follows: postmortem interval (PMI)5 h,
no argyrophilic grains, no cortical Lewy bodies, no evidence of fronto-
temporal dementia, no cancer in the brain parenchyma, and no infarc-
tions within 3 cm of the brain tissue samples. These neuropathological
confounds were assessed using standard neuropathological procedures
as described in detail previously (Nelson et al., 2007). Demented controls
were from the brains of patients with dementia with Lewy bodies (DLB),
in comparison with “pure” AD that lacked Lewy bodies. Five DLB pa-
tients were of ages 68, 82, 85, 87, and 90 years. Braak stages for these
patients were 2 or 3. Before RNA extraction, meninges and large vessels
were removed; gray matter was dissected away from white matter, and
only gray matter was used for these studies.
RNA was isolated from brain tissue cut from superior and middle
temporal cortex and separately from motor cortex. Subjacent tissue was
evaluated neuropathologically for all samples. Tissue (4–8 g) that had
been snap-frozen in liquid nitrogen and then transferred to a 80°C
freezer was thawed in isotonic lysis buffer with RNasin (160 U/ml; Pro-
mega, Madison, WI) and Complete protease inhibitor tablets (Roche,
Indianapolis, IN). Tissue was homogenized for 5 min on ice using a glass
and Teflon hand homogenizer followed by additional disruption with a
Microson XL2000 hand sonicator (Fisher Scientific, Waltham, MA)
(three times 10 s each on ice), and then the samples were centrifuged at
16,000 g for 15 min at 4°C. The supernatant was used for RNA isola-
tion. Trizol LS (Invitrogen, Carlsbad, CA) was used according to manu-
facturer’s instructions, except for an additional overnight20°C precip-
itation step during isopropanol precipitation. RNA quality was
confirmed using A260/A280 readings as well as banding pattern and RNA
Integrity Number using an Bioanalyzer (Agilent, Palo Alto, CA); de-
graded samples were discarded.
Microarraymethods and analyses.ThemiRCURYLabeling kit (Exiqon,
Woburn, MA) was used for target labeling and hybridization to a con-
ventional miRNA microarray. The oligonucleotide probe arrays were
printed on Codelink substrates, processed, and scanned at the University
of Pennyslvania Microarray Core Facility. Detailed methods with regard
tomiRNA labeling and hybridization are provided in supplemental file 1
(available at www.jneurosci.org as supplemental material).
cDNA microarrays: Affymetrix Exon Arrays. RNA for the cDNA mi-
croarrays was from the same temporal isocortex samples as used for the
miRNAmicroarray. Samples used were fromAD (n 3), mild cognitive
impairment (MCI) (n  4), and nondemented (n  4) brains. The
mRNA reverse transcription, labeling, hybridization, and other process-
ingwere performed exactly aswritten in theAffymetrix (SantaClara, CA)
technical manual. Exon Array data were also processed using the Af-
fymetrix Expression Console software, and using that software, normal-
Table 1. Cases used with neuropathological correlation
Temporal cortex Pathology Counts
Diffuse plaques Neuritic plaques NFT Braak stage PMI (h) Age
AD Case 1 47 15 17 6 3.5 87
Case 2 34 16 31 6 3 93
Case 3 50 30 31 6 3.33 84
Case 4 38 23 11 6 2.33 75
Case 5 18 22 35 6 4.5 84
Case 6 50 20 14 6 2.75 90
Average 40 21 23 6.0 3.2 85.5
MCI Case 1 7 9 1 3 2.45 97
Case 2 47 12 0 3 5 91
Case 3 0 0 0 3 2.75 93
Case 4 50 9 1 4 3.5 87
Case 5 22 14 0 3 2.9 82
Case 6 50 5 5 5 2 99
Average 29 8 1 3.5 3.1 91.5
Nondemented Case 1 4 6 0 1 4 91
with SMT Case 2 3 0 0 0 3.25 92
plaques Case 3 37 9 0 2 2.75 93
Case 4 17 2 0 2 2.4 87
Case 5 3 2 0 0 3.5 95
Average 13 4 0 1.0 3.2 91.6
Nondemented Case 1 0 0 0 2 1.66 85
without SMT Case 2 0 0 0 1 5 88
plaques Case 3 0 0 0 1 2.25 80
Case 4 0 0 0 1 1.75 86
Case 5 0 0 0 2 4 90
Case 6 0 0 0 1 2 76
Average 0 0 0 1.3 2.8 84.2
Cases used for miRNA microarray involved detailed evaluation, both prior and subsequent to patients’ death. Brain samples were obtained immediately
subjacent to tissue that was used for detailed neuropathological evaluation. Pathology counts represent a quantitation of neuropathological lesions as
described in detail previously (Nelson et al., 2007). SMT signifies the superior and middle temporal gyri. Note that, in these areas, there is a graded increase
in pathology between the four groups. NFT, Neurofibrillary tangle.
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ization was performed by using the gene level analysis, core annotation
confidence, median polish summarization method, and global median
normalization method.
Validation: in situ hybridization, Northern blots, andWestern blots.The
seven different cases used for ISH were not the same as the cases used for
any of the RNA expression profiling. For ISH, brain tissue from the
following were used: AD case 1, 80-year-old female, Braak stage 6; AD
case 2, 93-year-old female, Braak stage 5; AD case 3, 75-year-old male,
Braak stage 6; nondemented case 1, 92-year-old male, Braak stage 0;
nondemented case 2, 85-year-old female, Braak stage 0; nondemented
case 3, 77-year-old male, Braak stage 4 (pathology “probable AD”); de-
mented control with multiinfarct dementia related to cerebral amyloid
angiopathy and an anomalous pattern of neurofibrillary pathology, 87-
year-old male.
ISH was performed as described previously (Nelson et al., 2006) with
modifications. Tissue was obtained at autopsy, placed into 4% parafor-
maldehyde, and fixed for 24–36 h at 4°C. Tissue was then placed in 20%
sucrose overnight, again at 4°C. The following day, tissue was cut on a
freezing microtome at 25 m thickness and mounted onto coated glass
slides (VWR,West Chester, PA). After air-drying for 30 min, slides were
stored at80°C. For in situ hybridization, sections were first allowed to
equilibrate to room temperature and then treated with Proteinase K
(Roche; 40g/ml) for 20min at room temperature, followed by quench-
ing with glycine (Fisher Scientific; 1 mg/ml for 15 min). After PBS
washes, slides were immersed in 10% formaldehyde (Fisher Scientific; 10
min), washed again twice in PBS, and treated with acetic anhydride/
triethanolamine (Fisher Scientific; 10 min) at room temperature. Sec-
tions were then washed in PBS (four times, 10 min each) followed by 5
SSC (twice, 5 min each). Prehybridization was performed for 3 h at 37°C
is in a buffer prepared thus: 650ml of ultrapure formamide [EMD (Om-
nipur), Gibbstown, NJ]; 250 ml of 20 SSC; 1 ml of Tween 20; and 100
g/ml purified yeast RNA (Roche). LNAprobes (Exiqon)were diluted to
1.6M in prehybridization buffer. Care was taken not to refreeze diluted
LNA probes. For both miR-107 and miR-124 probes, hybridization was
performed at 37°C. After overnight hybridization, which was performed
with mechanical agitation, slides were washed at 37°C (twice with 5
SSC for 5 min, and then three times with 2 SSC in 50% formamide for
20 min each), followed by three washes in PBS with 0.1% Triton X-100
(PBST) at room temperature. Nonspecific antigen blocking was per-
formed at 4°C in PBSTwith 2% sheep serum (Jackson ImmunoResearch,
West Grove, PA) and 2 mg/ml RNase-free BSA [EMD (Omnipur)] for
2 h, followed by the addition of 1:1000 diluted AP-conjugated anti-
digoxigenin antibody (Roche) and incubation overnight at 4°C. The next
day, tissue is washed in PBST (four times 10 min each), and then in
staining solution (10 mM Tris-HCl, pH 9, 50 mM MgCl2, 100 mM NaCl,
0.1% Tween 20) twice for 5 min. Nitroblue tetrazolium and bromo-
chloroindoyl phosphate (Roche) at 50 mg/ml each were added, and the
staining reaction was at room temperature with gentle movement for
8–24 h. miR-24 and miR-204 were used in this application because the
former has nearly identical Tm with miR-107, and miR-204 has low
expression in the CNS and a low Tm.
Northern blots were performed as described previously (Nelson et al.,
2004) with somemodifications. The amount of RNA loaded in each well
was normalized to the amount of total RNA and tRNA levels as described
previously (Tang et al., 2007).
For Western blots, 20 g of total protein was loaded onto each lane.
BACE1 monoclonal antibody (R&D Systems, Minneapolis, MN) was
used at 1:1000. -Actin monoclonal antibody (Rockland, Gilbertsville,
PA) was used at 1:1000.
Bioinformatics: rna22-based predictions of putative miR-107 miRNA
targets prediction in BACE1 mRNA 3-untranslated region. To identify a
list of putative gene targets for the microRNAs of interest, we used the
rna22 algorithm described previously (Miranda et al., 2006). One
strength of rna22 is its ability to identify putativemicroRNAbinding sites
along the length of the entire mRNA transcript [i.e., in 3-untranslated
regions (UTRs) as well as 5-UTRs andCDSs].Moreover, rna22 does not
impose any cross-genome conservation constraints when determining
the targets of a miRNA. For the analyses described below, we focused
only on the 3-UTR of BACE1. Our studies also considered predictions
contained in other publicly available databases of predicted miRNA tar-
gets, as described in Results.
Validation: reporter vector constructs, transfection, and dual luciferase
assays. The evaluation of putative miRNA recognition elements (MREs)
in the 3-UTR of mRNAs was performed as described previously (Kiri-
akidou et al., 2004; Nelson et al., 2004) with modifications. To experi-
mentally test two of the predicted miR-107 MREs in the 3-UTR of
BACE1, reporter vectors bearing these binding sites were subcloned into
the mammalian expression vector pRL-TK (Promega) carrying the Re-
nilla luciferase gene (Rluc) as a reporter. Predicted miR-107 binding
sites, designated B1 (aatttaagtcgggaaattctgctgcttga) and B2 (attcccactg-
cacttggtgctgctttggc), which reside on BACE1 (NM_012104.3) 3-UTR
between 2208 and 2245 and between 3741 and 3774, respectively, were
inserted into the 3-UTR of Rluc gene at the XbaI and NotI restriction
sites as described previously (Kiriakidou et al., 2004; Nelson et al., 2004).
MutatedMREs (B1mut, aatttaagtcgggaaattcttggccttga; B2mut, attcccact-
gcacttgcgttgcgtttggc) containing sequence modifications predicted to af-
fect the “seed region” targeted bymiR-107were used as negative controls
such that the overall A/G/C/T nucleotide composition was not changed
between the B1/B1mut or B2/B2mut. To monitor the reporter system,
hsa-Let-7 MRE on LIN28 (LIN28), and its mutated sequence (M2) were
Figure1. miRNAexpression for a subset ofmiRNAs fromtemporal (superior andmiddlegyri)
cortex. Note that miR-107 levels are decreased significantly already in MCI cases and trends
toward a decrease in nondemented patients with incipient pathology. Although case-to-case
variance is considerable, a trend is clearly discernible for miR-107. miR-26a was chosen for
comparison because this miRNA has the closest expression to miR-107 on our microarray and
was subject to very similar global normalization parameters. Hence, ordinate values are the
same for A and B. The horizontal bars are the average for that condition. *p 0.005; **p
0.03, Student’s one-tailed t tests.
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used for positive and negative controls as de-
scribed previously (Kiriakidou et al., 2004; Nel-
son et al., 2004). Correct construct sequences
were confirmed by sequencing the 3-UTR of
Rluc gene on all of the pRL-TK vectors.
HeLa cells (American Type Culture Collec-
tion, Manassas, VA) were cultured under the
vendor’s recommended conditions. For the lu-
ciferase reporter assay, HeLa cells were plated at
a density of 4 105 per well in a 24-well plate a
day before transfection. Two separate transfec-
tions were performed, because otherwise the
plasmid and short interfering RNA (siRNA)
transfections interfered with each other (data
not shown). For the first transfection, 0.4 g of
Rluc-encoding pRLTK reporter plasmid along
with 0.2 g Firefly luciferase (Fluc)-encoding
PGL3 (Promega) control plasmid were trans-
fected using Lipofectamine 2000 reagent (In-
vitrogen) according to the manufacturer’s in-
structions. Transfected cells were washed in
antibiotic-free media after 6 h of transfection,
and the cells were allowed to recover overnight. Twenty-four hours after
the first transfection, cells were further transfected with 250 nM of either
miR-107 siRNA duplex (sequences: agcagcauuguacagggcuauca and
auagcccuguacaaugcugcguu), miR-320 siRNA duplex (sequences:
aaaagcuggguugagagggcgaa and cgcccucucaacccagcuuuguu), or only with
transfection reagent mixture, using siRMAX (Invitrogen) according to
manufacturer’s instructions. Luciferase reporter activity analysis was
performed 24 h after the siRNA transfection using Dual Luciferase Assay
System (Promega) and a Turner 20/20n luminometer (Fisher Scientific)
according to themanufacturers’ instructions. To control for transfection
efficiency, relative luciferase activity was calculated by normalizing the
RLuc (pRL-TK) to the Fluc (PGL-3) readouts. Each experimental condi-
tion was performed in triplicate within individual experiments, and the
results shown represent two independent experiments.
Results
miRNAmicroarray results
RNA was isolated from patients with different clinical and neu-
ropathological features as shown in Table 1. Note the short PMIs
and the detailed correlation with neuropathology from subjacent
tissue. Cases were separated into four groups: nondemented with
no/negligible AD-type pathology, nondemented with incipient
AD pathology, MCI with moderate AD pathology, and AD. The
expression patterns for most miRNAs were stable across the dif-
ferent clinical states. Approximately 200 different miRNAs were
expressed at levels above background on this array, but only70
miRNAs were detected at a high enough level to merit compara-
tive studies.
Among the fewmiRNAs that were consistently changed inAD
versus nondemented brains was miR-107 (Fig. 1). One-way
ANOVA shows that miR-107 shows a highly significant decrease
across the four groups at p 0.014. Of particular interest was the
unique decrease between miR-107 levels in nondemented pa-
tients without pathology versusMCI (Student’s t test, p 0.008),
suggesting that decreased miR-107 expression occurs in the ear-
liest stages of AD.
Other miRNAs differed between nondemented and AD pa-
tients but did not appear changed in the subclinical stages of AD.
miR-103 is a close paralog ofmiR-107, differing only at a single 3
base. The expression of miR-107 was 20% higher than miR-
103; however, as shown inTable 2,R2 (correlation coefficient) for
miR-107 and miR-103 readout for the microarray was 0.91.
Because the levels ofmiR-103 on themicroarray closelymirrored
miR-107, the miR-103 signal probably represents cross-
hybridization as would be expected on a Northern blot. In addi-
tion to a decreased expression of miR-107 in temporal cortex, a
trend for decrease in miR-107 was also seen in motor cortex in
AD brains (data not shown) (one-way ANOVA for motor cortex
is p  0.050; for motor cortex, n  19 different brains were
assessed). These changes seem to indicate global change in brain
miR-107 levels, even in areas less affected by AD pathology.
Among other highly expressed miRNAs, ANOVA analyses indi-
cate that miR-23b was also expressed at lower levels in AD brains
than nondemented brains ( p 0.015).
We decided to focus on changes in miR-107 because these
appeared to have the greatest statistical significance and emerged
very early in the progression of the pathology.Demented controls
are important to assess the specificity of the changes seen in AD.
For these controls, isocortex frompatientswithDLB (n 5)were
Figure 2. Northern blots were used to validate the microarray data indicating that miRNA
expression changes are seen in early AD pathogenesis. These results show that miR-107 levels
are decreased early in the development of AD, whereas the expression of other miRNAs trend
toward a slight increase. The miRNAs were chosen to represent a gamut of high and medium-
expression level miRNAs.
Table 2. Correlations between the expression of miRNAs and other genes
Gene(s) assignment
R2 correlation coefficient
versus miR-107
R2 correlation coefficient
versus miR-103
R2 correlation: other intronic
miRNAs versus mother mRNAs
miRNAmicroarray
miR-103 (	) 0.912
Exon array microarray
NM_148978//PANK1 (	) 0.06 (	) 0.14
NM_024960//PANK2 () 0.071 () 0.061
NM_024594//PANK3 (	) 0.16 (	) 0.236
miR-126 versus EGLF7 () 0.11
miR-128a versus R3HDM1 (	) 0.005
miR-342 versus EVL () 0.006
The degree to which the expression of different miRNAs is correlated with expression of other genes is described for miR-103, miR-107, and other intronic
miRNAs. The detected expressions ofmiR-103 andmiR-107 are very highly correlated on ourmicroarray, whichmay represent cross-hybridization. The other
comparisons show the correlation between the expression of various miRNAs, using the miRNA microarray, versus the expression of genes in which those
miRNAs are introns (n 11 using a Affymetrixmicroarray as for Fig. 7). miR-107 resides in PANK1; paralogousmiR-103 genes are present within PANK2 and
PANK3; miR-126 is intronic within EGFL7, as are miR-128a andmiR-342 within R3HDM1 and EVL, respectively. The (	) preceding the R2 numbers indicates
a positive correlation, whereas () indicates a negative correlation. None of the correlations between intronic miRNAs and their mother mRNAs were
statistically significant; an ANOVA to test the significance of the regression between miR-103 and PANK-3 mRNA levels was the lowest at 0.12.
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used, in comparison with nondemented patients (n  5) and
those with pure AD (n  2; positive control). A statistically sig-
nificant drop in miR-107 was not seen in the DLB cases. A one-
way Student’s t test for miR-107 levels in DLB versus nonde-
mented brains was p 0.29.
Validation: Northern blots and in situ hybridization
Microarray results were validated and extended using Northern
blots and ISH. For initial post hoc validation Northern blotting
(Fig. 2), we chose to evaluate the earlier stages of the disease
(nondemented with no pathology, nondemented with mild or
moderate pathology, and mildly cognitively impaired with mod-
erate pathology) because this is where the miR-107 decrease was
most significant and where the cellular populations are most
comparable. The findings by Northern blot were consistent with
those on the microarray; a number of miRNAs showed increased
expression in the early progression of AD, but miR-107 levels
decrease beginning early in the pathological evolution of the
disease.
In situ hybridization (Figs. 3-5) revealed that miR-107 is ex-
pressed strongly in human neurons, as we have shown miR-124
to be previously (Nelson et al., 2006). In addition, the miR-107
probe labels some cells that by morphology appear to be astro-
cytes. However, other miRNAs such as miR-24 stain white mat-
ter, which includes glial cells with far fewer neurons, more
strongly than miR-107 does (Fig. 3D,E). Different miRNAs ap-
pear to stain particular layering patterns in the hexalaminar iso-
cortex of the superior andmiddle temporal (SMT) gyrus. Specif-
ically, ISHwith amiR-124 probe labels the superficial (layers I/II)
and the deeper (layers IV/V) neuronal lamina. Even in relatively
advanced AD, the pattern of miR-124 ISH is maintained. In a
demented control brain with extensive cerebral amyloid angiop-
athy, miR-107 showed an identical staining pattern with distinct
superficial and deep layer staining. In contrast, in brain sections
with extensive AD pathology, miR-107 ISH still shows the super-
ficial layers are stained; however, the
deeper layers show a marked decrease in
miR-107 hybridization (Fig. 4). This de-
crease of miR-107 in deep layers was ob-
served also in a single nondemented case in
which there was significant AD pathology
(nondemented case 3 in Materials and
Methods with pathology showing probable
AD) (data not shown), an observation that
correlates with the microarray data show-
ing decreased miR-107 expression early in
the pathology (Fig. 1). The cortical lamina
with decreased miR-107 ISH signals coin-
cidewith cerebral cortical laminawhere the
neuropathological lesions of AD (thiofla-
vine S-positive plaques and tangles) are
seen (Fig. 4). In the perirhinal cortex, an
isocortical (six-layered) region affected
early by AD, ISH was performed on brain
tissue from two elderly nondemented cases
without appreciable pathology and com-
pared with two AD cases (Fig. 5 shows rep-
resentative photomicrographs from AD
case 3 and nondemented case 1 described
in Materials and Methods). In the AD
cases, miR-124 remained strongly ex-
pressed in the surviving neurons, whereas
miR-107 levels were decreased. In contrast,
in the nondemented controls, miR-107 signal was present at a
qualitatively higher level. These cases were different from the
cases in Figure 1 or 5, thus providing cellular level insights, and
independent replication.
miR-107 and BACE1: bioinformatic predictions
Having identified miR-107 as the miRNA with the most signifi-
cant expression decrease early in the progression of AD, we
sought to determine whether this change would have any impact
on AD-related genes including BACE1, BACE2, APP, and SNCA,
and others.We used the rna22 algorithm (Miranda et al., 2006) to
examine the corresponding 3-UTRs for potentialmiR-107 bind-
ing sites. This algorithm was chosen because rna22 does not rely
on cross-genome sequence conservation to report putative bind-
ing sites for the microRNA under consideration. Using the de-
fault parameter settings (Miranda et al., 2006), rna22 identified
five binding sites for miRNA miR-107 in the 3-UTR of BACE1
mRNA (Fig. 6A). Taking into account additional experimental
evidence (discussed below), which indicates that BACE1 is differ-
entially expressed (upregulated) in AD, we also considered the
possibility that miRNAs other than miR-107 may be involved in
the regulation of this gene. Analysis of the 3-UTR of BACE1
using rna22 indicates that at least 25 microRNAs from among
those listed in Release 9 of miRBase (Griffiths-Jones, 2006) have
three or more putative binding sites (Fig. 6B). More than one-
half of the miRNAs that rna22 predicts target BACE1 are ex-
pressed in brain tissue; however, in view of our differential ex-
pression profiling studies, we decided to focus on the interactions
betweenmiR-107 and BACE1 for this first analysis. Detailed pro-
vision of the predicted miRNA:mRNA pairings are presented as
supplemental file 2 (available at www.jneurosci.org as supple-
mental material). We also compared the predictions of rna22 to
those made by Pictar (Krek et al., 2005) and TargetScan (Lewis et
al., 2003). Across all the algorithms, we found that the 3-UTR of
most AD-related genes were not predicted to be targeted bymiR-
Figure 3. ISH performed on human brains shows that miR-107 is enriched in neurons. A is a photomicrograph of a nonde-
mentedpatient’s hippocampus at lowpower probed formiR-107 and shows CA1 andCA3 aswell as the dentate gyrus (dg).B and
C show higher-power photomicrographs, from the area boxed in 3A, with miR-107 (B) and miR-124 (C), another neuron-
enrichedmiRNA.miR-124 ISHwasperformedonanear-serial brain section.D, UnlikemiR-124,miR-107also stainswhitematter,
albeit indistinctly in most cases. E, However, other miRNAs such as miR-24 show much more distinct glial profiles (arrows) in
white matter. F shows a probe for the control miR-204, which was chosen because it has low CNS expression on microarray but
has a low Tm. Scale bars: A, F, 1 mm; B–E, 100m.
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107 (data not shown). With regard to
BACE1, one of the five sites predicted by
rna22, BACE1 (NM_012104.3) 3-UTR
between mRNA nucleotides 2208 and
2245, was also reported by PicTar and Tar-
getScan, although the latter two predicted
the site would be recognized by the paralo-
gous miRNAs including miR-16, which
have the identical seed sequence as miR-
107. The MREs predicted by the various
programs and their relative locations are
shown in Figure 6.
Correlating miRNA expression with
mRNA expression profiling microarrays
andWestern blot results
Because numerous recent studies have
shown that changes in miRNA levels lead
to altered levels of mRNA targets (Lim et
al., 2005; Wang and Wang, 2006; Grimson
et al., 2007), we performed correlative
mRNA studies on a subset of the cases of
nondemented (n  4), MCI (n  4), and
AD (n  3) brains using the same RNA
extracted from temporal cortex and used in
the miRNAmicroarray studies. The results
of these experiments with regard to BACE1
and miR-107 expression are shown in Fig-
ure 7. These experiments show a clear
trend: cases with lower miR-107 (which
tend to have more AD pathology) tend to
have higher BACE1mRNA than cases with
higher miR-107 and vice versa. Separate,
independent one-way ANOVA results in-
dicate that both the increase in BACE1
mRNA as well as the decrease in miR-107
levels were statistically significant ( p 
0.05). For comparison purposes, we show
analogous results for presenilin (PSEN1)
and for miR-125b in which such trends
were absent (Fig. 7B).
Having performed miRNA- and
mRNA-related profiling on the same 11 to-
tal RNA samples, we were able to also test
the correlation between the levels of in-
tronic miRNAs (such as miR-107 and the
paralogous miR-103s) and those of the
mRNAs of their “mother” genes. These re-
sults are shown in Table 2. The correlations
of expression were highest for both miR-
107 and miR-103 to PANK3  PANK1 
PANK2. This was surprising because miR-107 is present in
PANK1. Nonetheless, as with the correlations for other intronic
miRNAs and their mother genes, as shown in Table 2, none was
statistically significant.
mRNA and protein levels are frequently discrepant (Nelson and
Keller, 2007).Hence, we performed post hoc studies of six additional
aged humanpatients thatwere diagnosed as nondemented,MCI, or
AD, to correlate the expression of miR-107 and BACE1 protein as
detected by Northern andWestern blots, respectively. These results
are shown in Figure 7, C and D. These results show that, at the
protein level, as well as the mRNA level, a decrease of miR-107 and
an increase in BACE1 expression tend to be seen in AD brains.
Validation: tissue culture miRNA recognition element studies
Guided by the computational predictions presented above, we
focused on the two MREs that were consistently predicted by at
least the rna22 and PicTar methods. Their sequences are desig-
nated B1 and B2, respectively (Fig. 8). Each of the twoMREs was
subcloned separately into pRL-TK expression plasmids and as-
sessed in HeLa cells to determine its physiological relevance.
These experiments depend partly on endogenous miRNAs, and
miR-107 was originally described in a study of HeLa cells
(Mourelatos et al., 2002). Figure 8 shows the two sites B1 and B2
highlighted and also shows the sequences used and the results of
two different experiments (n 3 replicates each). A third exper-
Figure 4. ISH-stained cells and AD-type neuropathology each show cerebral cortical lamina-specific staining patterns in
humanbrains thatdiffer betweenADandcontrol. Theseexperimentswereperformedon superior andmiddle temporal gyri using
sections cut at 25m. Photomicrographs depict near-serial sections through the middle temporal gyri of three human brains;
pial surface is up. Thioflavine S shows green-fluorescent amyloid and neurofibrillary tangles. The top two cases were from AD
brains, and the bottom was from a profoundly demented stroke patient (mini-mental status examination score, 0); demented
control case, Thioflavine S shows cerebral amyloid angiopathy (CAA)with amyloid in small blood vessels (pink arrows). Note that
the superficial layers (lamina II; arrowheads) appear relatively spared inADbrain; however, inADbrain thedeeper layers (laminas
IV/V; asterisks) are severely depleted for miR-107 (left) but not miR-124 (right). The deeper, miR-107-depleted laminas are
vulnerable to AD pathology, compatible with the hypothesis that miR-107 depletion is associated with the development of AD
pathology. Scale bar: Top left, 500m (for photomicrographs).
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iment (n  3 replicates) showed the same result (data not
shown). To establish valid negative controls for particular MRE
sequences, we scrambled the seed region sequences of the B1 and
B2MREs, without changing the A/G/C/T content of the plasmid.
The highly similar control sequences were subcloned into sepa-
rate pRLTK plasmids. Compared with the control sequences, the
reporter assays showed that Rluc activity of the reporter carrying
B1MREwas clearly reduced as the result of endogenousmiRNAs
(Student’s t test, p  0.0001). This reduction was further aug-
mented by the addition of miR107 siRNAs, indicating the speci-
ficity of miR-107 action on this MRE. To confirm that siR107
action is specific, the unrelated siR320 was included in the exper-
iment. Addition of siR320 did not further decrease Rluc activity
as observed with siR107, but increased luciferase activity relative
to control, which may indicate a separate regulatory mechanism
or a possible compromise of miRNA function. Unlike MRE B1,
the subcloning of MRE B2 into the 3-UTR of pRLTK did not
have any effect on Rluc activity, suggesting that B2 putative MRE
is probably not anmiRNA recognition element or that it acts as a
MRE only in a specific context. In these experiments, the very
strong lin-28 MRE recognized by endogenous let-7 miRNAs and
its scrambled M2 were used as controls to monitor the reporter
assay system. The activity of the luciferase reporter bearing lin-28
MRE was dramatically reduced as result of endogenous let-7 ex-
pression inHeLa cells as seen previously (Kiriakidou et al., 2004).
Note that neither siR107 nor siR320 had any effect on the lucif-
erase activity of lin28 reporter.
Discussion
miR-107 levels are decreased in human cerebral cortical gray
matter early in the pathological progression of AD, as shown by
expression profiling using microarrays and Northern blots. In
situ hybridization on human cerebral cortex demonstrated that
miR-107 is strongly expressed in neurons with a characteristic
laminar expression pattern. Bioinformatics approaches predict
that as many as five different sites on the 3-UTR of BACE1
mRNA may be targeted by miR-107. Luciferase reporter assays
directly support the hypothesis that miR-107 regulates BACE1
through at least one discrete 3-UTR MRE. Together, these data
indicate that the change in neuronalmiR-107 expression contrib-
utes to the pathogenesis of AD.
There are several limitations to our data. The microarray we
used was unable to differentiate specifically between the paralogs
miR-103 and miR-107, which differ by a single nucleotide near
their 3 ends. Nonetheless, the signal levels referent to miR-107
spots were consistently higher than miR-103 on the arrays, sug-
gesting that miR-107 (and not miR-103) was likely the predom-
inant miRNA detected. In any case, because of their extreme
sequence identity and the location of their single-nucleotide dif-
ference, the target prediction algorithms would have generated
the same list of putative binding sites. Previous studies have in-
dicated that miRNA hybridization is not specific to the level of a
single-nucleotide difference at that part of the molecule (Kiri-
akidou et al., 2004; Goff et al., 2005). However, this issue will be
addressed in the immediate future.We alsowere surprised to find
a very low detection of miR-9 on this microarray platform. We
found discrepancies previously in miR-9 detection, which were
not linked to ourmicroarray platform, andmay indicate inherent
difficulty in phosphorylating or ligating to the UCUUU 5 se-
quence of miR-9 (data not shown). Notwithstanding this techni-
cal shortcoming, the total number of miRNAs expressed above
background is quite compatible with the previous findings of
other brain miRNA microarray studies (Baskerville and Bartel,
2005; Gaur et al., 2007; Tang et al., 2007).
In addition to potential cross-reaction on this specific mi-
croarray platform, there are other caveats that pertain to most
human studies. When performing human brain studies, control-
ling for all relevant variables is virtually impossible. In the current
study, we included important non-AD dementia controls,
namely DLB. Nonetheless, it is possible that different patient
groups will be treated subtly differently, or manifest distinct co-
morbidities and/or behaviors that cause different environmental
conditions (such as circadian rhythms and agonal states/medi-
cines) that might induce bias in miRNA expression patterns.
Our results indicate a regulatory mechanism involving mole-
cules, miR-107 and BACE1, heretofore not known to interact.
Between those molecules, far less is known about miR-107. The
nearly identical paralogs miR-107 and miR-103 (Mourelatos et
al., 2002) (miR-103/7) have been shown to be expressed in many
mammalian organs with highest concentration in brain tissue
(Babak et al., 2004; Baskerville andBartel, 2005;Wang andWang,
2006).miR-103/7 are differentially expressed in a number of con-
texts, including during development (Esau et al., 2004; Miska et
al., 2004), neoplastic transformation (Roldo et al., 2006), hypoxia
(Kulshreshtha et al., 2007), and both cold and heat stress (Marsit
et al., 2006; van Rooij et al., 2006).
Non-demented-Case1                Non-demented-Case 1                
Alzheimer’s disease--Case 3         Alzheimer’s disease-Case 3 
miR-124
miR-124
miR-107
miR-107
In situ hybridizaton: parahippocampal gyrus
Figure 5. ISH on perirhinal gyrus comparing nondemented elderly control and AD on near-
serial sections again shows that miR-107 levels are decreased in deep cortical lamina of AD
brain. These are from different patients from those in Figure 4, and the result was replicated on
other patients (see Results). Whereas miR-124 ISH signal remains strong in the neurons that
survive AD neurodegeneration, miR-107 signal is qualitatively lower in neurons in AD brain. In
contrast, in the nondemented elderly controls, both the neuronal miR-107 and miR-124 ISH
signals are more robust. Scale bar, 500m (for all four photomicrographs).
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Intriguingly, miR-107 expression may
relate to the coordinated regulation of a
pathway related to lipid metabolism (Wil-
fred et al., 2007). The DNA templates for
miR-107 andmiR-103 each exist within in-
trons in the genes that encode the panto-
thenate kinase (PANK) enzymes. In hu-
mans, there are at least three highly
homologous PANK genes. miR-103(1),
miR-103(2), and miR-107 reside within
PANK3, PANK2, and PANK1 genes, re-
spectively (Ying and Lin, 2005). The basic
arrangement of these miRNAs in PANK
genes remains constant through 500 mil-
lion years of vertebrate evolution (Wilfred
et al., 2007). PANK enzymes serve a uni-
versal catalytic function, namely, the phos-
phorylation of pantothenate (vitamin B5)
(Tahiliani and Beinlich, 1991). This is the
rate-limiting step in generating coenzyme
A (CoA), and PANKs are central enzymes
in the regulation of cellular CoA levels
(Leonardi et al., 2005). CoA is a necessary
cofactor in 4% of known enzymes, in-
cluding100 reactions involved inmetab-
olism (Leonardi et al., 2005).
The location ofmiR-103/7 genes within
introns of the PANK genes may be physio-
logically relevant. Expression levels of in-
tronic miRNAs and their host genes are in
some but not all circumstances well corre-
lated, presumably because they are co-
transcribed by RNA polymerase II
(Baskerville andBartel, 2005; Ying and Lin,
2005, 2006); however, we find that in our comparison of miRNA
and mRNA microarrays, the correlations for intronic miRNAs
andmothermRNAs was (from a statistical standpoint) nonexist-
ent. We speculate that the downstreammiRNA processing is dif-
ferentially regulated, or, conceivably, these intronicmiRNAsmay
be transcribed separately from the mRNAs. Additional work re-
mains to be performed in terms of the regulation of processing in
the context of intronic miRNAs.
BACE1 cleaves the -amyloid precursor protein creating the
neurotoxic -amyloid peptide A1–42 (Vassar et al., 1999; Haniu
et al., 2000). The dysregulation of BACE1 appears to directly
contribute to the pathogenesis of AD (Dominguez et al., 2004;
Durhamand Shepherd, 2006;Guo andHobbs, 2006; John, 2006).
Our ISH show that miR-107, like BACE1 (Bigl et al., 2000; Fuku-
moto et al., 2002), is enriched in neurons. A striking laminar
staining pattern is observed for miRNAs miR-107, miR-124, and
AD neuropathology alike. Laminas with evident decreased miR-
107 relative to miR-124 signal are vulnerable to developing AD
pathology. This correlation is by no means proof of the hypoth-
esis that decreases inmiR-107 levels cause increased vulnerability
to AD. Nonetheless, it is suggestive and demonstrates the impor-
tance of complementing tissue-level profiling modalities with
ISH.
Our computational analyses indicate thatmiR-107may target
BACE1mRNA posttranscriptionally through asmany as five dis-
tinct binding sites in the 3-UTR. One of these five sites was
common across three different target prediction algorithms.
However, it is entirely likely that the action ofmiR-107 onBACE1
is also effected by one ormore of the other predicted sites. Indeed,
experimental evidence, using reporter constructs with subcloned
MREs in HeLa cells, corroborates the computational predictions
that endogenous miR-107 participates in the regulation of
BACE1. These reporter constructs have been useful in previous
description of miRNA:mRNA interactions (Kiriakidou et al.,
2004, 2005, 2007; Nelson et al., 2004). Our data suggest that at
least one of the putative miR-107 MREs is physiologically rele-
vant, albeit less potent than the very strongly inhibitory let-7
MRE. Previous studies have supported a role for miRNAs in bi-
ologically important partial, as opposed to complete, suppression
of target mRNAs (Sevignani et al., 2006; Ying et al., 2006; Li et al.,
2007).
BACE1 genetic regulation is complex (Preece et al., 2003; La-
hiri et al., 2006; Li et al., 2006; Rossner et al., 2006; Mihailovich et
al., 2007; Stockley and O’Neill, 2007; Tesco et al., 2007) and has
been shown to occur partly posttranscriptionally (Marambaud et
al., 1998; Rossner et al., 2006). Different regulatory mechanisms
probably overlap in time and in cytoplasmic domains with mul-
tiple transcriptional, translational, and posttranslational pro-
cesses involved in BACE1 regulation. Because a pharmacological
regulation of BACE1 endopeptidase activity at its active site has
proved a challenge (Beher and Graham, 2005; Hull et al., 2006;
Ohno, 2006), each of these regulatory mechanisms represent an
alternative potential “handle” for altering BACE1 expression
pharmacologically.
Previous studies have suggested roles for miRNAs in neuro-
degenerative disease. Recent reviews have summarized these data
(Hebert and De Strooper, 2007; Nelson and Keller, 2007; Singh,
2007). One previous study has shown that particularmiRNAs are
Figure6. A, Agraphic depictionofBACE13-UTR sequence showing the locationof theMREs thatwerepredictedby rna22and
several other public-access miRNA target prediction databases. The asterisk denotes sequences that were predicted to be recog-
nized by homologous miRs (miR-15 family) that share the same seed sequence as miR-107. B, A partial list of microRNAs that
rna22 predicts target the BACE1 3-UTR; note that the list includes onlymicroRNAs that are predicted to target the BACE1 3-UTR
at three or more sites. Also shown are the starting locations for the five miR-107 binding sites that are predicted by rna22.
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altered in CA1 hippocampal cells of AD;miR-124, for example, is
increased (Lukiw, 2007). Our findings show a trend toward in-
creases in miR-124 levels in AD, but this trend is not statistically
significant. Another previous study has shown that amiRNAmay
be relevant in Parkinson’s disease and to normal dopaminergic
function (Kim et al., 2007). Furthermore, studies in mammals
and in invertebrates have suggested that miRNAsmay play a role in
neuroprotection (Bilen et al., 2006a,b).However, there have been as
yet no data suggesting a direct genetic link between miRNAs or
miRNA recognition elements and neurodegenerative disease. To-
gether, these observations may indicate that neurodegenerative
diseases like AD, which takes place over multiple decades rather
than just years (Scarmeas et al., 2005), tend to reflect a “down-
ward spiral” effect of multiple processes, andmiRNAsmay play a
contributory role.
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